A.O.U. Orbassano

Titolo:	Acalabrutinib Real World Italian Observational Study -Arise Italian Multicentric Observational Secondary Data Collection Study Of Acalabrutinib In The Treatment Of Patients With Chronic Lymphocytic Leukemia
Patologia:	Chronic Lymphocytic Leukemia
Tipo di Studio:	Non-interventional / observational, multicenter, longitudinal secondary data usage study based on a retrospective cohort of patients with CLL
Fase:	3
Principali criteri di inclusione:	All consecutive patients with CLL who received acalabrutinib according to Italian legislation dlg 219/2006 art.125 will be eligible for inclusion in the study, subject to site agreement and patient consent to participate. Patients must meet the following criteria for study entry: 1. Age ≥ 18 years old at the date of consent subscription. 2. Diagnosis of CLL. 3. Treatment of CLL with acalabrutinib at physician's discretion initiated between 1st May 2021 and 30th April 2022. 4. Informed consent to participate in the study and privacy form signed by the patient (or their legal representative).
Principali criteri di esclusione:	Patients who meet any of the following criteria will be excluded: 1. Acalabrutinib treatment initiation before 1st May 2021 or after 30th April 2022
Sede e contatti	AstraZeneca SpA MIND - Viale Decumano, 39 20157, Milano Italy M: +39 338 6764869 gianluigi.reda@astrazeneca.com